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OBJECTIVES: To suggest alterations to cost-effectiveness models of biologics for 
moderate to severe psoriasis that would account for the utility of partial 
responders. METHODS: Clinical guidelines dictate that, for the continuation of a 
biologic in treatment of moderate to severe psoriasis, a 75% improvement from 
baseline on the Psoriasis Area Severity Index (PASI) must be achieved which 
serves as a Minimum Clinical Endpoint (MCE). However, patients achieving a 
PASI 50% improvement may also continue treatment if supplemented by a 
minimally important difference (MID) in health-related quality of life (5-point 
improvement on the Dermatology Life Quality Index (DLQI)). Since cost-
effectiveness models of biologic medications for treatment of psoriasis do not 
account for the utility of any patients achieving a PASI 50% improvement, a 
systematic review was conducted to identify whether patients achieving a PASI 
50% improvement also achieved a 5-point DLQI improvement in large RCTs. 
Statistical inference from data obtained therein was used to modify equations 
used in cost-effectiveness calculations. RESULTS: The systematic review 
returned 8 studies that reported DLQI improvements in terms of Mean ± SD, 
stratified by increasing PASI response. Each study returned mean DLQI scores for 
patients with a PASI 50% improvement that were within one standard deviation 
of a 5-point DLQI improvement. This finding drove proposed alterations in which 
patients with a PASI 50% improvement are counted as “partial responders” or 
“non-responders” based on the probability of whether or not a 5-point DLQI 
improvement was attained. CONCLUSIONS: The literature confirms that 
patients with severe psoriasis can achieve a MID in DLQI improvement without 
achieving an MCE in PASI improvement. This study proposes alterations to the 
methodology of cost-effectiveness calculations that recognize the meaningful 
improvement in outcomes achieved by this subset of patients. Nevertheless, 
future studies should examine how these alterations affect overall cost-
effectiveness of biologics for psoriasis.  
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1Shanghai Health Development Research Center, School of Public Health, Fudan University, 
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OBJECTIVES: To apply national demographic and epidemiologic data in China to 
a mathematical model designed to estimate the public health impact of PCV7 at 
a population level. METHODS: Demographic data were collected from 2008 
census .The incidence rate of all-cause hospitalized pneumonia and 
pneumococcal meningitis was searched from international literature. Data were 
applied to a 10-year Markov model to estimate the impact of vaccination on 
those diseases. Projections of the diseases over a 10-year period are estimated 
under assumptions of no vaccination and full vaccination of the national birth 
cohort. Details of the model calculations as applied to the United States were 
published elsewhere. RESULTS: According to model estimation, over 730,000 
cases of pneumococcal meningitis and over 100 million cases of pneumonia that 
would occur in unvaccinated children and adults in China over a 10-year period, 
as well as causing over 5.3 million deaths. More than 30 million cases and 
420,000 deaths would occur in children under 5 years of age. The inclusion of 
universal vaccination of infants with PCV7 was expected to reduce the overall 
burden by 5.5 million cases, largely due to the reduction in all-cause pneumonia, 
with nearly 2 million cases of pneumonia estimated to be reduced in children 
under 5 years old. CONCLUSIONS: Widespread use of PCV7 in China is expected 
to have a significant impact on hospitalizations and death due to all-cause 
pneumonia and meningitis in vaccinated children.The potential impact of 
widespread use of PCV7 on unvaccinated persons due to herd protection adds to 
the overall public health impact significantly.  
 
PRM86  
HEALTH ECONOMIC MODELING METHODS FROM AN ACO PROVIDER 
PERSPECTIVE  
Gavaghan M, Hertz D, Garfield S 
GfK Bridgehead, Wayland, MA, USA  
OBJECTIVES: The traditional audience for US health economic (HE) models has 
been payers, but the changing health care reimbursement environment suggests 
a stronger role for provider-perspective models. The US health care system is 
moving toward quality incentive payment schemes and increased risk sharing 
for providers. This shift in payment will impact provider incentives and priorities 
as they relate to technology adoption. Here, we look at how the transition from 
fee-for-service payments to bundled payments in accountable care organizations 
(ACO) will impact health economic modeling for manufacturers of medical 
devices. METHODS: Expert analysis was conducted on a comprehensive review 
of publicly available literature, in-depth discussions with hospital and ACO 
administrators, and drawing on lessons learned from developing models for 
device manufacturers. Relevant model inputs, time horizon, outcomes and 
structure were examined to provide recommendations for improving the 
usefulness of HE models for hospital and ACO decision-makers. RESULTS: Of the 
6 administrators interviewed, 5 (83.3%) felt that technology adoption decisions 
will move beyond the individual physician and extend to the system-wide level. 
When asked to consider what outputs would be most useful for benefit design 
and coverage decision-making, administrators cited the total cost of procedure 
(include hospital length-of-stay and hospital resource utilization), post-operative 
care and cost associated with complications from the procedure, in rank order. 
ACO administrators reported that time horizons considered as part of budget 
impact modeling should be extended from the traditional benefit year to up to 3 
years, depending on the length of the episode of care. CONCLUSIONS: Medical 
device manufacturers need to create data and tools  
that demonstrate efficiency gains and cost-effectiveness from a hospital and 
ACO purchasing strategy. The ability to demonstrate both a clinical and 
economic value to hospitals and ACOs, who are increasingly the key decision-
makers for technology adoption, will be important to achieving successful 
market access.  
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OBJECTIVES: Where data is sparse, expert opinion may be used to populate 
decision analytic models. Elicitation techniques which capture uncertainty 
associated with expert opinion (i.e. elicit probability distributions) have analytic 
benefits over obtaining single values from experts but may be difficult to carry 
out and the methodological implications of different techniques are poorly 
understood. To assess current use of elicitation techniques which incorporate 
experts’ uncertainty, we conducted a methodological review of the use of 
elicitation in economic models. METHODS: The review was systematic in 
approach. Electronic databases (MEDLINE, EMBASE and CRD) were searched 
using an explicit strategy. Studies describing their approach to elicitation were 
included. Data was abstracted on pre-defined aspects of the elicitation 
technique. The synthesis was narrative. RESULTS: Twelve articles were included. 
The median number of experts per study was five (range 3-23). In eleven studies 
(91.7%), experts were asked individually. Only one study reported a group 
elicitation exercise. The most frequently used approaches to elicitation were the 
histogram technique and the bisection method. Elicitation was used to inform 
effectiveness (for treatments), performance (for diagnostic tests) or disease 
progression parameters, with only one study eliciting resource use. The elicited 
parameters were in the form of a proportion in seven studies, time to event in 
four studies, rate in three and relative risk in two studies. Across these studies, 
there was heterogeneity in both approach and reporting of what we considered 
to be key aspects of the elicitation process. CONCLUSIONS: Judged by the studies 
identified in the review, elicitation can be useful and is valued. Efforts should be 
made to improve reporting of elicitation in health technology assessments, with 
the aim of not only of improving the description of individual studies, but also to 
contribute towards establishing accepted good practice in elicitation in the 
context of decision analytic modeling.  
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OBJECTIVES: To figure out what disease models equations/hypothesis work best 
on what populations. METHODS: 1) Extraction of multiple published disease 
models/risk equations for cardiovascular disease and multiple diabetic 
population distributions and outcomes. The populations used were UKPDS, 
ASPEN, ADVANCE, ACCORD, NDR, KP. 2) Implementation of these components 
and systematic cross validation of models against populations using micro-
simulation and relying on computing power. 3) Defining a fitness score to 
convert of multiple outcome differences into a single number. 4) Defining 
different queries with weights to rank model / population fitness. The methods 
avoid using individual data and rely on more accessible summary data. 
RESULTS: The fitness score matrix uses color coding and ranking to visually 
demonstrate the fitness between 6/34 populations/cohorts and 64 combinations 
of published risk equations and hypotheses. The results show that different 
combinations of risk equations behave differently on different population 
cohorts. For each query, the system ranks the models. Models that implement 
the following two corrections generally behaved better: 1) Temporal correction 
for treatment improvement; 2) Biomarker change introduced in the first year. 
CONCLUSIONS: 1) Modelers should talk in terms of best fitting model rather than 
best model since in many cases, the best model changes according to specifics of 
the query. 2) Disease modelers who develop risk equations should add a 
temporal correction term within their risk equations to prevent model outdating. 
3) The fitness score function allows comparing behavior of different populations 
using a similar metric and provides a visual explanation of current 
understanding of disease progression.  
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PATIENT-LEVEL SIMULATION MODELING FOR ECONOMIC EVALUATIONS: 
OPPORTUNITIES AND CHALLENGES IN A PRACTICAL SETTING  
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RTI Health Solutions, Research Triangle Park, NC, USA  
OBJECTIVES: In the spectrum of methodologies used to conduct economic 
evaluations, patient-level simulation modeling is noteworthy for its flexibility in 
reproducing patient experiences that closely mirror reality. This flexibility is 
especially important when modeling diseases with continuous or multi-
dimensional health states or with non-Markovian dependence on disease 
history, but often comes at the expense of advanced data and software 
requirements and reduced computational efficiency. Methods for exploiting the 
opportunities while mitigating the challenges associated with using simulation 
modeling are needed. METHODS: Based on our experience developing patient-
level simulation models in Microsoft Excel for a complex, progressive disease, we 
identified steps that can be taken during the development and presentation of a 
simulation model to capitalize on the advantages inherent in the flexibility and 
transparency of this approach while mitigating some of the the associated 
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difficulties. RESULTS: Three methods were identified for mitigating the 
challenges of simulation modeling. First, the implementation of the model can 
be simplified by minimizing the dependence on random number draws 
wherever possible. For example, a single, cumulative probability of treatment 
discontinuation can replace a series of separate, time-dependent discontinuation 
probabilities. Second, the transparency and efficiency of the computations can 
be improved by anticipating all the random draws required to determine a 
patient’s experiences and organizing the calculations so that a sufficient batch of 
random numbers can be generated at the beginning of the patient’s sojourn 
through the model. Lastly, and perhaps most importantly, the face validity of the 
model can be ensured through the visual representation of sample patient 
experiences that highlight the ability of the model to more accurately represent 
reality. CONCLUSIONS: Our modeling experiences have demonstrated that 
meaningful steps can be taken to capitalize on the flexibility of patient-level 
simulation modeling while maintaining critical aspects of transparency and 
efficiency.  
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Shao H1, Shi L1, Li S2, Xu L2 
1Tulane University, New Orleans, LA, USA, 2Shandong University, Jinan, China  
OBJECTIVES: To classify each of the stakeholders in National Essential Drug 
System(NEDS) in China by three major attributes: power, legitimacy and urgency. 
To predict the outcome of the whole system by using the Stakeholder Impact 
Index (SII). To evaluate the current performances of each main stakeholder and 
identify definitive stakeholders and dangerous stakeholders. To develope a 
circular model for NEDS based on indexes collected by Delphi method. 
METHODS: A circular model has been developed to map all major stakeholders 
in the NEDS using quantitative data collected by Delphi method involving 36 
experts with experience in implementation of essential drug policy were 
interviewed. RESULTS: The central government in the circular model for 
essential drug system was a dominant stakeholder of the whole stakeholder 
system. The provincial governments were definitive stakeholders while local 
governments and medical institutions were dependent stakeholders. 
Furthermore, media and drug stores were dormant stakeholders, pharmaceutical 
manufacturers and distribution enterprises were dangerous stakeholders. 
Patients, community residents and medical insurance programs were 
discretionary stakeholders. The Stakeholder Impact Index for the NEDS was 
positive (SIIproj* = 2.72). CONCLUSIONS: Our finding indicates that the overall 
anticipation of national essential drug policy is optimistic. Provincial 
governments, which should be in the position of leading the implementation of 
essential drug policy, need to be given more autonomy and the constrcution of 
an experience exchanging platform within provinces in the form of annual 
symposium, seasonal meeting, learning class or video conferences may 
accelerate the pace of implementation of national essential drug policy. 
Pharmaceutical manufacturers and distribution enterprises should be taken 
more seriously care of in order to make sure they follow the policy rather than 
devastate it for their own benefits. Constructing a fare, balanced and self-
sustained bidding platform may be the key solution for preventing such a 
phenomenon.  
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THE EXPECTED VALUE OF SAMPLE INFORMATION FROM THE 
PHARMACEUTICAL PERSPECTIVE UNDER CONDITIONS OF VALUE BASED 
PRICING  
Watson P, Brennan A 
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OBJECTIVES: To modify the traditional framework for conducting ENBS, which is 
not compatible with drug development in the pharmaceutical industry. 
METHODS: We modify the traditional framework for conducting ENBS and make 
it more relevant to the pharmaceutical industry. Traditional approaches to ENBS 
value trials according to the expected benefits to society and the price of the 
intervention is assumed to be fixed. We use expected profit forecasts to value 
trials and assume that the price of the drug is variable and conditional on the 
trial outcomes. Value Based Pricing (VBP) is a pricing strategy where drug prices 
are generated in a CE model according to the cost-per-QALY threshold. We use 
this criterion to determine price. We assume that there is a threshold price 
below which the company would not market the new intervention and would 
receive zero profits. The expected price varies as different trial characteristics 
are simulated. A case study in which the sample size and trial duration are 
varied in a Phase III trial for Systemic Lupus Erythematosus (SLE). For each trial 
design we sampled 1000 trial outcomes. VBP was estimated for each simulated 
trial using a SLE CE model. Expected profit of the trial is estimated by averaging 
across all trial samples. ENBS is calculated as the expected profits minus the 
costs of the trial. RESULTS: A clinical trial with longer follow-up generated 
greater ENBS than a shorter trial with larger sample size. There is large variation 
in the expected profits for the clinical trials. CONCLUSIONS: ENBS can be 
adapted to value clinical trials in the pharmaceutical industry to optimise the 
expected profits. However, the analyses can be very time-consuming to run for 
complex CE models.  
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ASSESING PARAMETER IMPORTANCE IN HEALTH ECONOMICS MODELS. CAN 
WE MAKE IT FASTER?  
Milev S1, Coyle D2 
1CADTH, Ottawa, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada  
Uncertainty in parameters is present in many risk assessment and decision 
making problems and leads to uncertainty in model predictions. Therefore an 
analysis of the degree of uncertainty around the model inputs is often needed. 
Importance analysis involves use of quantitative methods aiming at identifying 
the contribution of uncertain input model parameters to output uncertainty. 
Expected value of partial perfect information (EVPPI) measure is a current gold- 
standard technique for measuring parameters importance in health economics 
models. The current standard approach of estimating EVPPI through performing 
double Monte Carlo simulation (MCS) can be associated with a long run time. 
OBJECTIVES: To investigate different importance analysis techniques with an 
aim to find alternative technique with shorter run time that will identify 
parameters with greatest contribution to uncertainty in model output. 
METHODS: A health economics model was updated and served as a tool to 
implement various importance analysis techniques. Twelve alternative 
techniques were applied: rank correlation analysis, contribution to variance 
analysis, mutual information analysis, dominance analysis, regression analysis, 
analysis of elasticity, ANCOVA, maximum separation distances analysis, 
sequential bifurcation, double MCS EVPPI, EVPPI-quadrature and EVPPI- single 
MCS method. RESULTS: Among all these techniques, the dominance analysis 
resulted with the closest correlated calibrated scores when compared with EVPPI 
calibrated scores. CONCLUSIONS: Performing a dominance analysis as a 
screening method to identify subgroup of parameters as candidates for being 
most important parameters and subsequently only performing EVPPI analysis on 
the selected will reduce the overall run time.  
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OBJECTIVES: A study of recently published health economic models found that 
face/internal validation, while recommended by ISPOR guidelines, was reported 
in less than half and third party validation (performed by individuals outside of 
the model building process with no stake in model results) was utilized in less 
than ¼ of published models. This study follows up on those primary results to 
investigate whether the rates of face, internal, and third-party model validation 
varies by type of publication, type of model, and geographic region. METHODS: 
The published models (n=136) from the primary study were categorized by type 
of publication (HEOR or non-HEOR), by type of model (cost-effectiveness analysis, 
cost-utility analysis, budget impact analysis, or other), and by geographic region 
(North America, Europe, or rest of the world). The rate of face and internal 
validation for each category was aggregated and compared. The analysis was 
also supplemented with additional published modeling studies for categories 
with limited numbers of studies from the primary analysis. The primary study’s 
methodology for determining model validation was followed for the 
supplemental models. RESULTS: The percentage of models that were either face/ 
internally validated varied with respect to the region, publication type, or type of 
model. Among the three different categories analyzed, each failed to conduct 
model validation at greater than a 50% rate. More specifically, the universally 
lowest method of validation by authors in all categories surveyed was through 
the use of a third party. CONCLUSIONS: Whether models were published in 
different types of journals, from a variety of countries, or varied by type of 
model, the rate of validation was similarly low throughout the published 
scientific literature. While the rate varies among the model characteristics 
analyzed, the results suggest that, regardless of model characteristic, ISPOR 
validation guidelines are not widely followed.  
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OBJECTIVES: The purpose of the study was to compare pharmacy-based  
and diagnosis-based indexes in predicting the total health care expenditure  
in current year and next year for the adult asthmatic population. METHODS: 
Data from panel 11 involving asthmatic patients aged 18 years or more were 
selected from the 2006-2007 Medical Expenditure Panel Survey (MEPS)  
The diagnosis-based index was coded according to the D’Hoore version of  
the Charlson comorbidity index, and the pharmacy-based index was defined 
using Chronic Disease Score-1 (CDS-1). The performance of both indexes  
was evaluated for the current year and next year. Additional variables included 
in the multivariable model were demographic characteristics, the number  
of prescribed medications and refills (NPM), and the number of emergency visits. 
RESULTS: The mean age (± Standard Deviation) in the study was 47.48±0.87 years 
and the mean total health expenditure was $8,285±500. Most of the selected 
patients were female (68%) and the vast majority of them were white (82%). The 
CDS-1 (adj R2 for current year=0.2483, and adj R2 for next year = 0.2469) 
performed better than D’Hoore (adj R2 for current year=0.1286, and adj R2  
for next year = 0.1271) when they were added individually. The best predictive 
model included age, sex, NPM, and either D’Hoore (adj R2 for current year = 
0.4334 and adj R2 for next year =0.4294) or CDS-1 (adj R2 for current year =0.4346 
and adj R2 for next year =0.4304). CONCLUSIONS: The best predictive model  
for the current and the prospective year was the model that includes 
demographics, number of prescriptions, and either pharmacy-based or 
diagnosis-based indexes  
